|Articles|March 1, 2017
March 2017: Big Data, Big Opportunity in Life Sciences
Author(s)LexisNexis
The big data transformation is poised to seep through the life sciences universe, promising to eliminate hundreds of billions of dollars of annual costs in the U.S. biopharmaceutical segment alone.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
WHO Prioritizes Three Experimental Treatments for Bundibugyo Ebola Strain
2
FDA’s Advisory Panel Votes in Favor of Updating Covid-19 Vaccine Shots to Target XFG Variant
3
CVS Restores Coverage of Lilly’s Zepbound, Adds Oral Obesity Drug Foundayo
4
FDA's Timeline for DTC Prescription Drug Ad Oversight
5